NAFDAC approves production of chloroquine batch for clinical trial

The National Agency for Food and Drug Administration and Control (NAFDAC), has approved the production of a batch of chloroquine for clinical trials.

The Director-General of the agency, Mojisola Adeyeye, made the announcement on Friday.

According to Adeyeye, NAFDAC was not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of the clinical trial.”

“NAFDAC is not approving Chloroquine as a product that can be used for Coronavirus because there is no submission to us for registration, but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore, the medicine is being approved just for the clinical trials,” Adeyeye said.

Furthermore, she called on experts and researchers that are interested in doing a clinical trial on Chloroquine to approach approved outlets.

© 2020, https:. All rights reserved., Attribution and link to is required if you wish to use any of the articles on this site


No Comment.